Claims for Patent: 9,895,431

Summary for Patent: 9,895,431

Title:	Simian adenoviral vectors encoding malaria antigen
Abstract:	The invention provides recombinant adenoviral vectors which are capable of eliciting immunity against the pre-erythrocytic stage of the life cycle of the malaria parasite. In particular, the invention provides a recombinant, replication deficient simian adenoviral vector which encodes an antigen comprising the thrombospondin-related adhesion protein (TRAP), and also immunogenic compositions (e.g. vaccines) comprising the vector and methods of using such compositions.
Inventor(s):	Reyes; Arturo (Oxfordshire, GB), Hill; Adrian (Oxfordshire, GB), O\'Hara; Geraldine (Oxfordshire, GB), Colloca; Stefano (Rome, IT), Cortese; Riccardo (Rome, IT)
Assignee:	GLAXOSMITHKLINE BIOLOGICALS SA (Rixensart, BE)
Application Number:	12/595,576
Patent Claims:	1. A recombinant replication defective simian adenovirus vector capable of eliciting a protective response to Plasmodium berghei challenge in mice, comprising a nucleotide sequence encoding a multiple epitope thrombospondin-related adhesion (ME.TRAP) protein comprising SEQ ID NO:2, said nucleotide sequence operably linked to regulatory sequences which direct expression of said ME.TRAP protein in mammalian cells, wherein the simian adenoviral vector is replication defective chimpanzee adenovirus isolate 63 (AdCh63). 2. The recombinant replication defective simian adenovirus vector of claim 1 wherein the regulatory sequences which direct expression of said ME.TRAP protein comprise a CMV promoter. 3. The recombinant replication defective simian adenovirus vector of claim 2 wherein the regulatory sequences comprise the promoter of the HCMV IE1 gene and a fragment of the 5' untranslated region of the HCMV IE1 gene including intron A. 4. An immunogenic composition comprising the recombinant replication defective simian adenovirus vector of claim 1 admixed with one or more pharmaceutically acceptable vehicles, carriers, diluents or adjuvants. 5. A method of eliciting an immune response against ME.TRAP protein comprising SEQ ID NO:2 in a human subject, which comprises administering to the subject an amount of the immunogenic composition of claim 4 which is sufficient to elicit said immune response in said subject. 6. The method of claim 5 wherein the immunogenic composition is administered in an amount sufficient to elicit a T-cell-mediated response against ME.TRAP protein comprising SEQ ID NO:2. 7. The method of claim 5 wherein the immunogenic composition is administered as a single dose immunization.

Details for Patent 9,895,431

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2027-04-10
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2027-04-10
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2027-04-10